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Gene Transfer of Glutamic
Acid Decarboxylase Reduces
Neuropathic Pain
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We tested whether transfer of the gene coding for glu-
tamic acid decarboxylase to dorsal root ganglion using a
herpes simplex virus vector to achieve release of GABA in
dorsal horn would attenuate nociception in this condi-
tion. Subcutaneous inoculation of a replication-defective
herpes simplex virus vector expressing glutamic acid de-
carboxylase (vector QHGAD67) 7 days after selective L5
spinal nerve ligation reversed mechanical allodynia and
thermal hyperalgesia; the antiallodynic effect lasted 6
weeks and was reestablished by reinoculation. QH-
GAD67 inoculation also suppressed induction of c-Fos
and phosphorylated extracellular signal–regulated kinase
1 and 2 in the spinal cord.
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Peripheral neuropathic pain is a common and difficult
to treat concomitant of polyneuropathy or structural
nerve injury. Opioids are relatively ineffective, and
their use is limited by side effects. Antidepressants and
anticonvulsants have demonstrated efficacy in random-
ized controlled trials but provide only 50% relief in less
than half of patients treated.1 Among the complex
mechanisms underlying neuropathic pain, partial nerve
injury results in a selective loss of GABAergic inhibi-
tory synaptic currents in spinal cord2 that contribute to
abnormal pain sensitivity and the phenotypic features
of the neuropathic pain syndrome. GABAergic agents
have not been widely used in the treatment of neuro-
pathic pain because the therapeutic window of these
agents is modest and the dose is limited by side effects.
Gene transfer represents a novel and useful means to
target expression of peptides to focal sites within the
nervous system. We have shown that transduction of
sensory neurons of the dorsal root ganglion (DRG) by
footpad inoculation with herpes simplex virus (HSV)-
based vectors can be used to achieve a regional antino-
ciceptive effect. HSV vectors coding for proenkephalin
or the glial cell–derived neurotrophic factor produce an
antihyperalgesic and antiallodynic effect in rodent
models of inflammatory pain, neuropathic pain, and
pain resulting from cancer in bone,3–6 and an HSV-
vector expressing glutamic acid decarboxylase (GAD)
provides an analgesic effect in the central neuropathic
pain syndrome resulting from spinal cord injury.7 In
this study, we examined the antinociceptive effect of
GAD expressed from an HSV-based vector in the spi-
nal nerve ligation (SNL) model of neuropathic pain in
the rat.
Materials and Methods
The nonreplicating HSV vector QHGAD67, which is defec-
tive in expression of the HSV immediate early genes ICP4,
ICP22, ICP27, and ICP47 and contains the human GAD67
gene under the control of the human cytomegalovirus imme-
diate early promoter in the UL41 locus, has been described
previously.7 The control vector QOZHG is defective in the
same HSV genes but contains the green fluorescent protein
and Escherichia coli lacZ reporter genes.7
Male Sprague–Dawley rats weighing 225 to 250gm un-
derwent selective L5 SNL, as described previously,5 with the
approval of the University Committee on Use and Care of
Animals. One week after SNL, 30l of vector (either QH-
GAD67 or QOZHG, 4  108 plaque-forming units per
milliliter) was injected subcutaneously in the plantar surface
of the left hind paw, ipsilateral to the ligation. Mechanical
allodynia induced by SNL was determined by assessing the
response of paw withdrawal to von Frey hairs of graded ten-
sile strength as described previously,5,8 with a tactile stimulus
producing a 50% likelihood of withdrawal determined using
the up-down method.9 Thermal hyperalgesia was determined
using a Hargreaves apparatus,10 recording the time to with-
drawal from a radiant thermal stimulus positioned directly
under the hind paw.
Results
After L5 SNL, rats displayed a significant decrease in
the magnitude of the mechanical stimulus necessary to
evoke a brisk withdrawal response to von Frey hair
stimulation (Fig 1A) and a significant reduction in la-
tency to withdraw from a heat stimulus (thermal hy-
peralgesia; see Fig 1B). Rats inoculated with QH-
GAD67 showed a statistically significant increase in
mechanical threshold beginning 1 week after inocula-
tion. The antiallodynic effect of QHGAD67-mediated
GABA expression was sustained and continuous, last-
ing 5 to 6 weeks and peaking at 2 weeks after inocu-
lation (see Fig 1A). The peak value of mechanical
threshold, 8.6gm, was close to the preoperative value.
By 7 weeks after inoculation, the antiallodynic effect of
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vector transduction disappeared, and the mechanical
threshold of QHGAD67-injected rats was identical to
that of control rats. Reinoculation into the same paw
with the same dose of QHGAD67 reestablished the
antiallodynic effect (see Fig 1A).
SNL induced a decrease in the thermal latency from
10.7 to 6.5 seconds, which lasted 3 weeks before grad-
ually recovery. Rats inoculated with QHGAD67
showed a statistically significant increase in thermal la-
tency in the ipsilateral paw beginning 1 week after in-
oculation (see Fig 1B), an effect that was sustained and
continuous, lasting 3 to 4 weeks (see Fig 1B). Sham-
operated animals had no change in mechanical thresh-
old or thermal latency (data not shown).
Expression of c-Fos and phosphorylated extracellular
signal–regulated kinase 1 and 2 (p-ERK1/2) induced
by gentle touch is one indirect biological marker of no-
ciceptive processes.11 Three weeks after SNL, gentle
touch was applied once every 4 seconds for 10 min-
utes, with the flat surface of the experimenter’s thumb
to the rat’s paw, and the number of immunoreactive
cells (anti–c-Fos or anti–p-ERK1/2 antibodies; Santa
Cruz Biotechnology, Santa Cruz, CA) detected avidin-
biotin horseradish peroxidase followed by nickel-
enhanced diaminobenzidine (Vector Laboratories, Bur-
lingame, CA).12 The number of Fos-LI–positive
neurons was substantially increased ipsilateral to SNL
compared with sham-operated control rats (Fig 2), and
inoculation of vector QHGAD67 significantly reduced
the number Fos-LI–positive neurons in laminae I–VI
(see Fig 2). p-ERK1/2 expression in laminae I and II
was also increased in rats after gentle touch stimulation
with SNL, and that increase was blocked in animals
inoculated with QHGAD67 (Fig 3).
Discussion
These results demonstrate that subcutaneous inocula-
tion of an HSV vector expressing GAD to transduce
DRG in vivo attenuated the behavioral manifestations
of mechanical allodynia and thermal hyperalgesia in a
model of peripheral neuropathic pain; the effect on be-
havior was confirmed by histological measures showing
a block in the induction of expression of c-Fos and
p-ERK1/2 in the ipsilateral spinal dorsal horn. We
have demonstrated previously that transduction of pri-
mary sensory neurons with QHGAD67 results in the
release of GABA from those cells in vitro and from
sensory nerve terminals in spinal cord in vivo.7 Subcu-
taneous inoculation of the vector results in transduc-
tion of both large and small neurons in the DRG, as
determined by immunocytochemical detection of GAD
expression.7 GABA release from transduced cells is
constitutive and is mediated by the GABA transporter
type 1 (GAT-1). In the spinal cord hemisection model
of central neuropathic pain, transduction of DRG by
subcutaneous inoculation of QHGAD67 in both hind
paws reduces below-level mechanical allodynia and
thermal hyperalgesia.7 This study is the first applica-
tion of this vector to peripheral neuropathic pain.
In the spinal cord, GABA is found primarily in in-
Fig 1. Antinociceptive effect of QOGAD67 in neuropathic pain. (A) L5 spinal nerve ligation (SNL) caused a significant decrease
in the threshold to tactile stimulation, which persisted for more than 4 months. Subcutaneous inoculation of QHGAD67 (arrow)
produced an antiallodynic effect reflected in an increase in the mechanical threshold. Reinoculation of QHGAD67 7 weeks after the
initial inoculation (arrow) reestablished the antiallodynic effect. Results are expressed as mean  standard error of the mean. (open
circles) QHGAD67; (closed circles) QOZHG; *p  0.05; **p  0.01; n  8 animals per group. (B) L5 SNL also caused a
significant thermal hyperalgesia, which persisted for 6 weeks. Inoculation with QHGAD67 (arrow), but not QOZHG, reversed the
thermal hyperalgesia induced by spinal nerve injury. *p  0.05; **p  0.01 versus QOZHG-inoculated; n  8 animals per
group. The statistical significances of the differences were determined by analysis of variance (StatView 5.2; SAS Institute, Cary,
NC) corrected for the number of post hoc comparisons using Scheffé’s F test.
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terneurons of the superficial dorsal horn predominantly
in laminae II and III that form axoaxonic synapses on
primary afferent terminals and axodendritic synapses
on projection neurons. Tonic GABAergic inhibition
plays an important role in normal sensory processing,
as indicated by increased behavior responsiveness13
and electrophysiological activity in spinal nociceptive
neurons14 after spinal administration of the GABAA
antagonist bicuculline to normal animals and by the
development of mechanical allodynia after spinal ad-
ministration of the GABAB receptor antagonist
CGP35348.15
The mechanical allodynia that results from selective
SNL can be reversed by the GABAB agonist baclofen
16
or the GABAA agonist muscimol,
17 and both mechan-
ical allodynia and thermal hyperalgesia after spinal
nerve injury are reversed by the GABAA agonist
4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol (isogu-
vacine) and baclofen.18 These findings are consistent
with observations of loss of GABA activity in dorsal
horn after chronic constriction injury of sciatic nerve,19
a decrease in GABAA receptor–mediated inhibitory
postsynaptic potentials, reduction of GAD65, and evi-
dence of apoptosis in dorsal horn in both the chronic
constriction and spared nerve injury models of neuro-
pathic pain.2 Transgene-mediated GABA released in
the dorsal horn acts at both GABAA and GABAB re-
ceptors. As we have demonstrated previously, the an-
tinociceptive effect produced by QHGAD67-mediated
GABA release can be partially blocked by the GABAA
antagonist bicuculline or by the GABAB antagonist
phaclofen.7
GABAergic therapy for neuropathic pain has had
limited success. Gene transfer offers the possibility of
targeted alteration in the neurotransmitter phenotype
to produce the local release of selected neurotransmit-
ters. Among the many viral and nonviral vectors that
may be used for gene transfer, HSV, because of its nat-
ural neurotropism and high-affinity retrograde trans-
port in sensory neurons, is uniquely suited for modify-
ing neurotransmitter release in dorsal horn after
subcutaneous inoculation.20 We have found previously
Fig 2. Effect of QHGAD67 on Fos-LI in dorsal horn. (A) Fos-LI in dorsal horn induced by 10 minutes of gentle tactile stimula-
tion was markedly increased in rats inoculated with QOZHG 1 week after spinal nerve ligation (SNL) and tested 2 weeks later (3
weeks after SNL). (B) This increase was blocked in rats with SNL that had been inoculated with QHGAD67 1 week after SNL
and tested 2 weeks later (3 weeks after SNL), and it was found in laminae I–VI of dorsal horn. Results are expressed as mean 
standard error of the mean. **p  0.01; n  5 animals per group. The difference between sham-operated and SNL animals inoc-
ulated with QOZHG was also statistically significant (p  0.01).
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that HSV-mediated transfer of proenkephalin produces
a sustained antiallodynic effect in the SNL model of
neuropathic pain,5 and that similar results can be
achieved with a vector expressing glial cell–derived
neurotrophic factor.6 The magnitude of the antiallo-
dynic effect achieved with the GAD67-expressing vec-
tor is substantially greater than that produced by either
the proenkephalin- or glial cell–derived neurotrophic
factor–expressing vectors. We propose that this differ-
ential effect reflects the role of reduced spinal GABAer-
gic tone in the pathogenesis of neuropathic pain and
the selective ability of QHGAD67 to correct that def-
icit locally. The results suggest that this novel approach
may prove useful in the treatment of neuropathic pain.
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An LRRK2 Mutation as a
Cause for the Parkinsonism
in the Original PARK8
Family
Manabu Funayama, PhD,1 Kazuko Hasegawa, MD, PhD,2
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We detected a missense mutation in the kinase domain of
the LRRK2 gene in members with autosomal dominant
Parkinson’s disease of the Japanese family (the Sagami-
hara family) who served as the basis for the original de-
fining of the PARK8 Parkinson’s disease locus. The re-
sults of the Sagamihara family, in combination with the
unique pathological features characterized by pure nigral
degeneration without Lewy bodies, provided us with
valuable information for elucidating the protein struc-
ture–pathogenesis relationship for the gene product of
LRRK2. We did not detect this mutation or other known
mutations of the LRRK2 gene in Japanese patients with
sporadic Parkinson’s disease.
Ann Neurol 2005;57:918–921
Parkinson’s disease (PD) [MIM 168600] is one of the
most common neurological disorders and is character-
ized by rigidity, bradykinesia, tremor, and postural in-
stability. Although PD is a sporadic disease in most
cases, various hereditary forms presenting clinical pheno-
types similar to those of sporadic PD have been recog-
nized. Molecular genetic studies on these familial forms
of parkinsonism have substantially advanced our under-
standing of the molecular pathogenesis of this disease.1–6
In a previous study, we identified a new locus for
PD, PARK8 (12p11.2-q13.1), by genome-wide linkage
From the 1Division of Clinical Immunology, Kitasato University
Graduate School of Medical Sciences; 2Department of Neurology,
National Hospital Organization, Sagamihara National Hospital,
Sagamihara; 3Kawashima Neurological Clinic, Fujisawa; 4Kitasato
University, Sagamihara; and 5Department of Neurology, Tokyo
University, Tokyo, Japan.
Received Dec 27, 2004, and in revised form Mar 11, 2005. Ac-
cepted for publication Mar 11, 2005.
Current address for Dr Funayama: Research Institute for Diseases of
Old Ages, School of Medicine, Juntendo University, Tokyo, Japan.
Published online May 4, 2005 in Wiley InterScience
(www.interscience.wiley.com). DOI: 10.1002/ana.20484
Address correspondence to Dr Obata, Department of Immunology,
Kitasato University School of Allied Health Sciences, 1-15-1 Kita-
sato, Sagamihara, Kanagawa 228-8555, Japan.
E-mail: obata@ahs.kitasato-u.ac.jp
918 © 2005 American Neurological Association
Published by Wiley-Liss, Inc., through Wiley Subscription Services
